Open Access

Table 1

Radionuclides considered in this study: physical half-life, physical or pharmaceutical form, medical application, and administered activity.

Radionuclide Physical half-life (days) Physical or pharmaceutical form Medical application Administered activity
phosphorus-32 14.3 Phosphate Polycythemia 260 MBq
strontium-89 50.7 chloride
(Metastron®)
Bone metastasis (palliative) 150 MBq
yttrium-90 2.7 Citrate or silicate (colloid) Radiation synovectomy 225 MBq
ibritumomab tiuxetan
(Zevalin®)
Non-Hodgkin lymphoma 1.2 GBq
SIR-sphere®
(microspheres)
Liver cancers (radioembolization) 2 GBq
Therasphere®
(microspheres)
Liver cancers (radioembolization) 5 GBq
indium-111 2.8 Pentetreotide Tumors overexpressing somatostatin receptors 6.7 GBq
iodine-131 8.0 Iodide Benign thyroid diseases 700 MBq
800 MBq
Iodide Thyroid cancer 1.5 GBq
3.7 GBq
5.6 GBq
MIBG Adrenal cancers
(pheochromocytoma, neuroblastoma, etc.)
5.6 GBq
7.4 GBq
Lipiodol (Lipiocis®) Liver cancers (radioembolization) 2.2 GBq
samarium-153 1.95 EDTMP
(Quadramet®)
Bone metastasis (palliative) 4 GBq
holmium-166 1.1 QuiremSpheres®
(microspheres)
Liver cancers (radioembolization) 12 GBq
erbium-169 9.4 Citrate (colloid) Radiation synovectomy 750 MBq
lutetium-177 6.7 [177Lu][DOTA0, Tyr3]
octreotate
(Lutathera®)
Intestine tumours 7.4 GBq
PSMA
(Pluvicto®)
Metastatic prostate cancers 7.4 GBq
rhenium-186 3.8 Citrate (colloid) Radiation synovectomy 370 MBq
radium-223 11.4 Dichloride
(Xofigo®)
Bone metastasis 6 MBq
actinium-225 10.0 PSMA-617 Metastatic prostate cancers 15 MBq

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.